- 4 days & nights inpatient stay
- 1 quick follow-up appointment
This clinical trial has been approved by an independent ethics committee.
About the study
The medication is being developed as a potential new treatment for idiopathic pulmonary fibrosis (IPF), a disease that causes progressive, irreversible damage to the lungs. IPF typically affects adults over the age of 40. Currently there is a need for an effective treatment for those with IPF.
This medication works by preventing the spread of fibrosis (scarring) in IPF patients.
How do I find out more?
If you have already registered with us but would like more information about this study, please call 1800 243 733 or schedule a call back. You can also email us at firstname.lastname@example.org quoting “Respiration Study”.
If you are interested in participating and have not previously registered as a participant with us, fill in your details in the form below and we’ll be in touch soon!